2026 Q2 Portfolio Activity
In 2026 Q2, SR ONE CAPITAL MANAGEMENT, LP maintained a portfolio of 17 distinct positions. The most significant new addition was Avalyn Pharma, Inc, now representing 10.48% of the total fund value. Conversely, SR ONE CAPITAL MANAGEMENT, LP completely exited their position in Arcellx, Inc..
Position History
hover any row below to update
Loading…
Total Positions
17
Quarter
2026 Q2
Top Holding
MANE (28.4%)
Top 10 Concentration
95.1%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-17 of 17
SR ONE CAPITAL MANAGEMENT, LP Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MANE
Veradermics, In...
|
Healthcare | 28.42% | 16.57% |
#1
1
Prev: #2
|
7.0 |
—
|
no change | no change |
P
S
|
2,401,868 | $295,285,652 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
ZBIO
Zenas BioPharma...
|
Healthcare | 12.31% | 10.76% |
#2
1
Prev: #3
|
6.5 |
—
|
no change | no change |
P
S
|
5,037,854 | $127,860,735 | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
CRSP
CRISPR Therapeu...
|
Healthcare | 10.70% | 10.59% |
#3
1
Prev: #4
|
6.0 |
—
|
no change | no change |
P
S
|
2,038,763 | $111,194,134 | 2024 Q1 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
AVLN
Avalyn Pharma, ...
|
Healthcare | 10.48% | — |
#4
Prev: #—
|
8.0 |
—
|
3,308,649 | — |
NEW
|
3,308,649 | $108,920,725 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
DSGN
Design Therapeu...
|
Healthcare | 9.09% | 7.59% |
#5
Prev: #5
|
5.1 |
—
|
no change | no change |
P
S
|
6,526,476 | $94,438,108 | 2021 Q4 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
ODTX
Odyssey Therape...
|
Healthcare | 6.83% | — |
#6
Prev: #—
|
6.2 |
—
|
3,794,883 | — |
NEW
|
3,794,883 | $71,002,261 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
ALMS
Alumis Inc.
|
Healthcare | 5.31% | 4.72% |
#7
Prev: #7
|
3.1 |
—
|
no change | no change |
P
S
|
1,959,896 | $55,151,473 | 2024 Q2 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
ORIC
ORIC Pharmaceut...
|
Healthcare | 4.81% | 6.39% |
#8
2
Prev: #6
|
2.4 |
—
|
100,455 | 2.2% |
P
S
|
4,615,384 | $49,984,609 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
MLYS
Mineralys Thera...
|
Healthcare | 4.06% | 4.63% |
#9
1
Prev: #8
|
2.6 |
—
|
no change | no change |
P
S
|
1,563,966 | $42,195,803 | 2023 Q2 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
SPRY
ARS Pharmaceuti...
|
Healthcare | 3.09% | 3.52% |
#10
1
Prev: #9
|
2.2 |
—
|
no change | no change |
P
S
|
4,012,903 | $32,143,353 | 2022 Q4 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
MOBI
Mobia Medical, ...
|
Healthcare | 2.56% | — |
#11
Prev: #—
|
4.5 |
—
|
1,986,072 | — |
NEW
|
1,986,072 | $26,613,365 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
NKTX
Nkarta, Inc.
|
Healthcare | 0.91% | 0.77% |
#12
Prev: #12
|
1.4 |
—
|
no change | no change |
P
S
|
3,333,333 | $9,433,332 | 2022 Q2 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
OCS
Oculis Holding ...
|
Healthcare | 0.86% | 1.86% |
#13
2
Prev: #11
|
1.3 |
—
|
no change | no change |
P
S
|
641,022 | $8,890,975 | 2025 Q1 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
RARE
Ultragenyx Phar...
|
Healthcare | 0.44% | 0.32% |
#14
Prev: #14
|
1.2 |
—
|
no change | no change |
P
S
|
137,753 | $4,599,573 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
ENGN
enGene Holdings...
|
Healthcare | 0.12% | 0.56% |
#15
2
Prev: #13
|
1.0 |
—
|
no change | no change |
P
S
|
747,750 | $1,293,607 | 2024 Q2 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
ORKA
Oruka Therapeut...
|
Healthcare | 0.00% | 2.31% |
Sold All 😨
(Was: #10) |
0.0 |
—
|
-430,330 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-12 | |||
|
ACLX
Arcellx, Inc.
|
Healthcare | 0.00% | 29.43% |
Sold All 😨
(Was: #1) |
0.0 |
—
|
-2,346,630 | -100.0% |
CLOSED
|
— | $— | 2022 Q1 | 13F Filing | 2026-06-30 | 2026-08-12 |
Showing 1-17 of 17 holdings